SYED USAMA AKHTAR
Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology BEAUMONT, TX NPI 1124060124
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology TX NOVARTIS PHARMACEUTICALS CORPORATION All categories
General Payments — all program years on this page
$2,026.27
- Category: General Payments
- Program years: PY2018–2024
- Record count: 82
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,162.31 across 52 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,087.32 | 51 |
| Education | $74.99 | 1 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $145.38 | 7 |
| Daiichi Sankyo Inc. | $89.41 | 2 |
| PFIZER INC. | $89.15 | 5 |
| Janssen Biotech, Inc. | $86.91 | 5 |
| Astellas Pharma US Inc | $72.68 | 4 |
| JAZZ PHARMACEUTICALS INC. | $70.38 | 2 |
| Acerta Pharma LLC | $58.16 | 2 |
| Tempus AI, Inc | $57.93 | 2 |
| E.R. Squibb & Sons, L.L.C. | $47.16 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $46.60 | 2 |
| EISAI INC. | $45.64 | 2 |
| Celgene Corporation | $40.93 | 2 |
| Merck Sharp & Dohme Corporation | $38.27 | 2 |
| Regeneron Healthcare Solutions, Inc. | $36.61 | 2 |
| Gilead Sciences, Inc. | $25.95 | 1 |
| GENZYME CORPORATION | $25.35 | 1 |
| Rigel Pharmaceuticals, Inc. | $24.99 | 1 |
| Kite Pharma, Inc. | $23.90 | 1 |
| Genmab U.S., Inc. | $22.68 | 1 |
| Genentech USA, Inc. | $20.77 | 1 |
| PUMA BIOTECHNOLOGY, INC. | $20.77 | 1 |
| Janssen Pharmaceuticals, Inc | $19.92 | 1 |
| BeiGene USA, Inc. | $19.92 | 1 |
| Incyte Corporation | $19.60 | 1 |
| Deciphera Pharmaceuticals Inc. | $13.25 | 1 |
By program year
Records — PY2024 (52)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.